Nasdaq:US$40.98 (-0.83) | HKEX:HK$70.40 (-7.20) | AIM:£5.92 (+0.14)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors